论文部分内容阅读
目的：分析西格列汀联合二甲双胍治疗2型糖尿病的临床疗效。方法：选择我院2015年3月～2015年10月期间收治的129例2型糖尿病患者作为研究对象，根据治疗方式的不同随机将患者分为西格列汀组（43例）、二甲双胍组（43例）、联合组（43例），二甲双胍组给予患者二甲双胍治疗，联合组给予患者西格列汀联合二甲双胍治疗，西格列汀组给予患者西格列汀治疗，记录和观察患者空腹血糖、餐后2h血糖、糖化血红蛋白。结果：三组患者治疗前后FBG、2hPBG、HbA1c指标水平均下降，西格列汀组FBG、2hPBG、HbA1c指标水平优于二甲双胍组（P<0.05）；联合组FBG、2hPBG、HbA1c指标水平明显低于西格列汀组（P0.05）结论：西格列汀联合二甲双胍治疗2型糖尿病的临床疗效显著，能有效改善患者各项指标情况。“,”Objective To investigate the clinical effect of sitagliptin combined with melbine in treating diabetes mellitus type 2.Methods 129 cases with diabetes mellitus type 2 in our hospital from March 2015 to October 2015 were selected and divided into sitagliptin group (n=43), melbine group (n=43) and combining group (n=43). Sitagliptin group was given sitagliptin treatment, combining group was given sitagliptin combined with melbine, melbine group was given melbine treatment. Recorded and observed fasting blood-glucose, 2 hour postprandial blood glucose, glycosylated hemoglobin of the patients.Results FBG、2hPBG、HbA1c levels declined after treatment of the patients, FBG、2hPBG、HbA1c index levels of sitagliptin group were better than melbine group(P<0.05); FBG、2hPBG、HbA1c index levels of combining group were obviously lower than sitagliptin group (P0.05).Conclusion Sitagliptin combined with melbine in treating diabetes mellitus type 2 has significant effect and can improve indicators of patients.